1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Regulatory News In Brief

FDA issues final rule on good manufacturing practices for combination products. Rule withdrawn on scientific misconduct policy. More regulatory news.

FDA will issue a long-awaited final rule Jan. 22 on current good manufacturing practice (CGMP) requirements for combination products. The rule clarifies which manufacturing quality requirements apply when drugs, devices and biological products are combined to create combination products. The rule finalizes a September 2009 proposed rule, which itself took four years to develop. (See Also see "Proposed Rule Defines Good Manufacturing Practices For Combo Products" - Medtech Insight, 28 September, 2009..) The regulation also lays out a streamlined approach for firms that make single-entity or co-packaged combo products at the same facility. These firms can adopt one operating system as the baseline, and then add additional procedures as needed. FDA notes that the final rule is “largely identical” to the proposed rule. The agency made minor adjustments based on the 25 comments it received on the proposal.

FDA will also issue a draft guidance document Jan. 22 on submissions for post-approval modifications to a combination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Where Do Questions Surrounding The EU’s AI Act Leave The Medtech Industry?

 
• By Amanda Maxwell

The EU’s Artificial Intelligence Act, which entered into force on 1 August 2024, is already facing turbulence.

Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

More from Policy & Regulation

Global Medtech Guidance Tracker: May 2025

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.

More Haste Less Pace? Challenging The ‘Early As Possible’ Principle In Medtech Innovation

 
• By Stuart Grant

The rallying cry to start as early as possible has become increasingly common in the world of medical device development. Innovation expert Dr. Stuart Grant challenges this conventional wisdom, asking: Is "sooner" truly better, or is there a smarter path to market for your medical device?

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.